Artiva Biotherapeutics To Reduce Workforce By ~94% Following Discontinuation Of AlloNK Development
Strategic Alternatives and Corporate RestructuringArtiva’s Board of Directors is evaluating internal options and potential strategic alternatives intended to maximize stockholder value. Leerink Partners has been engaged
Artiva is cutting almost all its workers and stopping a medicine project. When a company does this, it means the project did not work out as hoped.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.